A couple in bed, one partner sleeping and snoring, the other frustrated and awake.
Photo by Kampus Production on Pexels
i
How we researched this
We did not test these products in-house. Rankings are based on published clinical trials, meta-analyses, and adverse-event data. We evaluated design features (adjustability, material), evidence strength for snoring reduction, and documented side-effect profiles from FDA adverse-event databases and long-term adherence studies. Full methodology

Our current pick

SnoreRX ★ Editor's pick
$60

SnoreRX offers micro-adjustable mandibular advancement in 1 mm increments, addressing the patient-selection issue documented in a 2025 institutional outcomes analysis. A 2024 RCT comparing two MAD designs found that adjustability improved both efficacy and compliance. While no long-term data exists specifically on SnoreRX, the 10-year adherence study showed custom-titratable devices achieve 68% long-term use, versus 42% for fixed-position appliances. The evidence does not support the $60 price premium over simpler designs for every user, but adjustability matters if you have variable symptoms or want to minimize side effects through precise titration.

Evidence strength
7.0
Long-term adherence
68%
Side-effect risk
Moderate
If you buy through links in this guide, we may earn a commission. This doesn't affect our rankings.

How we evaluated mandibular advancement devices for snoring

We scored each mandibular advancement device for snoring on three dimensions: evidence strength (meta-analyses and RCTs documenting snoring reduction), long-term adherence (the 10-year data shows titratable devices retain 68% of users versus 42% for fixed-position models), and documented side-effect profile (the 2022 meta-analysis covering 36 studies found dental and skeletal changes occur with extended use). 8 2

Adjustability proved decisive. The 2025 predictors study found that inability to titrate mandibular advancement to the minimum effective protrusion correlated with both treatment failure and higher side-effect burden. A 2024 RCT comparing two different MAD designs confirmed that devices permitting incremental adjustment showed superior compliance and efficacy outcomes. 7 4

All 1 finalists, compared

Product HP % Course Evidence Sensitivity Price Buy
SnoreRX
★ Editor's pick
Micro-adjustable MAD Nightly Moderate Moderate $60 Where to buy →

Evidence rating reflects independent trial support for the product's concentration and protocol, not manufacturer studies. Scroll table sideways on small screens.

The 1 we recommend

SnoreRX ★ Editor's pick
$60

SnoreRX offers micro-adjustable mandibular advancement in 1 mm increments, addressing the patient-selection issue documented in a 2025 institutional outcomes analysis. A 2024 RCT comparing two MAD designs found that adjustability improved both efficacy and compliance. While no long-term data exists specifically on SnoreRX, the 10-year adherence study showed custom-titratable devices achieve 68% long-term use, versus 42% for fixed-position appliances. The evidence does not support the $60 price premium over simpler designs for every user, but adjustability matters if you have variable symptoms or want to minimize side effects through precise titration.

Evidence strength
7.0
Long-term adherence
68%
Side-effect risk
Moderate
Where to buy →

Skip these

3 of the 1 kits we reviewed performed poorly enough, on evidence, value, or sensitivity, that we recommend against them regardless of price.

Non-adjustable boil-and-bite devices under $30 $20 to $40
The 2025 predictors study found that inability to titrate mandibular advancement correlated with both treatment failure and higher side-effect burden. Fixed-position devices also showed 42% adherence at 10 years versus 68% for titratable appliances. You are paying less up front but accepting lower likelihood of long-term success.
Any MAD without professional fitting if you have active periodontal disease N/A
The 2022 meta-analysis of side effects documented dental movement and occlusal changes in 36 studies. Active gum disease increases risk of tooth mobility and accelerated bone loss under the forces exerted by mandibular advancement. A 2025 FDA adverse-events analysis found dental complications were the most common reported adverse event category.
MADs marketed for diagnosed obstructive sleep apnea without sleep study N/A
The 2018 comprehensive review concluded that while MADs reduce snoring and mild OSA, CPAP remains the first-line treatment for moderate to severe OSA (AHI greater than 15). Self-treating diagnosed OSA with an over-the-counter device delays effective therapy and carries cardiovascular risk. The 2025 institutional outcomes analysis found that patient selection (based on sleep study data) was the strongest predictor of MAD success.

If strips aren't right for you

Strips suit most people, but not everyone. Depending on your situation:

Dentist-fitted custom mandibular advancement device , For moderate to severe OSA, significant dental work, or previous MAD failure
Custom appliances fabricated from dental impressions offer superior fit and retention. Cost ranges from $1,800 to $3,200 including professional fitting and follow-up adjustments. The 2023 systematic review found custom devices showed higher efficacy than over-the-counter options, though the difference narrowed when OTC devices were adjustable. Insurance may cover custom MADs with prior authorization following a sleep study.
Hale Breathing (nasal dilator) , For snoring driven primarily by nasal obstruction, not tongue-base collapse
Internal nasal dilators open the nasal valve without mandibular repositioning. A 2024 RCT found nasal dilators reduced snoring in patients with isolated nasal resistance but were ineffective for tongue-base obstruction, the primary mechanism MADs address. $29.99 for a starter set, no dental side effects, but narrower indication.
Continuous positive airway pressure (CPAP) , For diagnosed obstructive sleep apnea (AHI greater than 15)
The 2018 comprehensive review concluded that CPAP remains the first-line treatment for moderate to severe OSA. A 2023 meta-analysis found CPAP showed superior AHI reduction compared to MADs, though adherence rates were similar (68% for titratable MADs, 65% for CPAP at 10 years). Insurance typically covers CPAP following a sleep study. Out-of-pocket cost ranges from $500 to $3,000.
Positional therapy devices , For position-dependent snoring (occurs only when sleeping on back)
The 2024 RCT compared MAD to combined positional therapy and found MAD superior for supine snoring, but positional devices (worn on back or chest to prevent supine sleep) work for patients who snore only on their back. A home sleep study can determine if your snoring is position-dependent. Cost: $50 to $200, no dental concerns.

Sources

  1. Beri A, et al. Appliances Therapy in Obstructive Sleep Apnoea: A Systematic Review and Meta-Analysis. Cureus. 2023. Cureus 2023 PubMed
  2. Tsolakis IA, et al. Dental and Skeletal Side Effects of Oral Appliances Used for the Treatment of Obstructive Sleep Apnea and Snoring in Adult Patients. J Pers Med. 2022. J Pers Med 2022 PubMed
  3. Ioerger P, et al. Mandibular Advancement vs Combined Airway and Positional Therapy for Snoring: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2024. JAMA Otolaryngol Head Neck Surg 2024 PubMed
  4. Yu L, et al. Clinical study of two mandibular advancement devices in the treatment of Obstructive Sleep Apnea: a pilot randomized controlled trial. BMC Oral Health. 2024. BMC Oral Health 2024 PubMed
  5. Al Khouri T, et al. An analysis of adverse events associated with Mandibular Repositioning Appliances (MRA). Respir Med. 2025. Respir Med 2025 PubMed
  6. Nanda N, et al. Patient Selection for Efficacious Mandibular Advancement Device Therapy in Obstructive Sleep Apnea: An Institutional Outcomes Analysis. Ann Otol Rhinol Laryngol. 2025. Ann Otol Rhinol Laryngol 2025 PubMed
  7. Paddenberg-Schubert E, et al. Predictors of disease alleviation with mandibular advancement devices in obstructive sleep apnea: a retrospective cohort study. Head Face Med. 2025. Head Face Med 2025 PubMed
  8. Abruzzi CM, et al. Long-term mandibular advancement appliance therapy for obstructive sleep apnea: Adherence and outcomes over 10 years. J Am Dent Assoc. 2025. J Am Dent Assoc 2025 PubMed
  9. Liao J, et al. A pilot randomized trial of a novel digital mandibular advancement device with customized lip bumper. BMC Oral Health. 2025. BMC Oral Health 2025 PubMed
  10. Hamoda MM, et al. Oral Appliances for the Management of OSA: An Updated Review of the Literature. Chest. 2018. Chest 2018 PubMed
We cite primary research wherever possible. We are not affiliated with or endorsed by any cited organization.